StreetAlpha.app
Home › Stocks › BNTX

BioNTech SE (BNTX)

Healthcare
$80.96
▼ −0.52%
LAST CLOSE · NOV 20

BioNTech develops immunotherapies for cancer and infectious diseases and sells the COVID-19 vaccine Comirnaty. It last closed at $80.96 on Nov 20, down 0.52% on the day. Over the last 12 months BNTX insiders bought $0 of stock on the open market and sold $89.8M, according to SEC Form 4 filings.

AI Auto Pilots
Is BNTX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BNTX.

Key Stats

Fiscal 2025
Results
Revenue
EUR 2.9B
+4.3% vs a year ago
Net income
−EUR 1.1B
−39.6% margin
Free cash flow
EUR 280.9M
9.8% margin
Operating margin
−49.0%
−EUR 1.4B operating income
Balance sheet
Cash & equivalents
EUR 7.7B
At Dec 31
Shareholder equity
EUR 19.2B
CEOUğur Şahin
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: EUR 19.0BEUR 19.0BFY2021FY2022: EUR 17.3BEUR 17.3BFY2022FY2023: EUR 3.8BEUR 3.8BFY2023FY2024: EUR 2.8BEUR 2.8BFY2024FY2025: EUR 2.9BEUR 2.9BFY2025

From BNTX's SEC filings, latest 20-F/A for the period ending Dec 31, 2025 (filed Jul 30). Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
EPS and revenue estimates
Year-ago EPS
Same quarter last year
Options-implied move
Move priced in by options
Analyst consensus
Ratings from the last 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on BNTX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on BNTX

Technical Analysis

BNTX · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 7% below its 20 day and 13% below its 50 day average. It is 17% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), near oversold. The nearest support is the Pivot S1 at $79.86, and the nearest resistance the Pivot at $81.36.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 3.3%/day
Key levels
$124.0052 week high+53.2%
$95.09200 day average+17.5%
$94.19100 day average+16.3%
$91.5250 day average+13.0%
$91.46Swing high (Nov 4)+13.0%
$86.3220 day average+6.6%
$82.46Pivot R1+1.9%
$81.36Pivot+0.5%
$80.96Last close
$79.86Pivot S1−1.4%
$79.5252 week low−1.8%
Indicators
RSI (14)31.46Weak, oversold below 30Neutral
MACD-2.50Below its signal lineBearish
Stochastic4.2Near the bottom of its rangeOversold
ADX (14)19.1No clear trend
Williams %R-93.8Oversold below −80, overbought above −20Oversold
CCI (20)-208.8Oversold below −100, overbought above 100Oversold
Rate of change−7.5%Change over 10 sessionsBearish
ATR (14)$2.65Typical daily range, 3.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BNTX

What happened before

See how BNTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow BNTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How BNTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for BNTXHow many large options trades hit BNTX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

BNTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲147 buying vs 125 selling
  • ●Shares held by funds +0.1%
  • ▲Funds holding +20
  • ▲Superinvestors: 3 added, 1 cut
  • ▲Put/call 1.05 to 0.20
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding304284+7.0%
In funds' top 10550.0%
Held by funds–––
New / increased57 / 9039 / 91+13.1%
Reduced / sold out88 / 3772 / 30+22.5%
Put/call ratio0.201.05−80.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BNTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

BNTX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$89.8M15 sales · 2 insiders
100% of the selling was under pre-arranged trading plans.
2026-04 sold $5.5M2026-09 sold $63.7M2026-10 sold $20.6MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 9Ugur SahinCEOSale plan63,209$94.07$5.9M
Oct 7Ugur SahinCEOSale plan24,000$95.86$2.3M
Oct 6Ugur SahinCEOSale plan93,000$97.14$9.0M
Oct 2Ugur SahinCEOSale plan34,000$97.09$3.3M
Sep 30Ugur SahinCEOSale plan66,000$98.19$6.5M
Sep 28Ugur SahinCEOSale plan61,000$98.57$6.0M
Every insider buy and sale for BNTX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See BNTX insider trades →

From SEC Form 4 filings by BNTX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BNTX is in one of them and how their past BNTX trades turned out.

BNTX in the AI portfolios
Loading…

BNTX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BNTX in an article yet. Here's the latest on the wider market.

BNTX in the news

BNTX Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Sep 12
Who traded BNTX · since 2023
Latest 5 filings of 8
$1K – $15KTraded Aug 7, 2025Filed Sep 12, 2025
$1K – $15KTraded Sep 3, 2024Filed Oct 3, 2024
Josh GottheimerSell (partial)
$1K – $15KTraded Aug 30, 2024Filed Sep 11, 2024
$1K – $15KTraded Apr 15, 2024Filed May 15, 2024
$1K – $15KTraded Mar 14, 2024Filed Apr 7, 2024
PersonTypeAmountTradedFiledDelay
Valerie HoyleD · ORSell$1K – $15KAug 7, 2025Sep 12, 202536 d
Josh GottheimerD · NJSell$1K – $15KSep 3, 2024Oct 3, 202430 d
Josh GottheimerD · NJSell (partial)$1K – $15KAug 30, 2024Sep 11, 202412 d
Josh GottheimerD · NJBuy$1K – $15KApr 15, 2024May 15, 202430 d
Josh GottheimerD · NJSell$1K – $15KMar 14, 2024Apr 7, 202424 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About BioNTech SE

BioNTech is a biotechnology company based in Mainz, Germany, that develops medicines based on the immune system. Its main focus is cancer, with further work on vaccines and therapies for infectious diseases, using messenger RNA and protein-based technologies. Its marketed product is Comirnaty, a COVID-19 vaccine sold through partners such as Pfizer and Fosun Pharma in many countries. Its customers are mainly public health authorities and healthcare systems that buy vaccines. Most of its other products are still being tested in clinical trials.

Headquarters
Mainz, Germany
Founded
2008